XORTX Therapeutics, Inc. (XRTX)
0.845
0.00 (0.00%)
USD |
NASDAQ |
Nov 10, 16:00
0.845
0.00 (0.00%)
After-Hours: 16:36
XORTX Therapeutics Enterprise Value : 0.4684M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 0.4684M |
| November 06, 2026 | 0.5808M |
| November 05, 2026 | 0.5982M |
| November 04, 2026 | 0.7193M |
| November 03, 2026 | 0.7366M |
| November 02, 2026 | 0.7539M |
| October 30, 2026 | 0.7366M |
| October 29, 2026 | 0.7885M |
| October 28, 2026 | 0.8231M |
| October 27, 2026 | 0.9097M |
| October 26, 2026 | 0.8404M |
| October 23, 2026 | 0.5983M |
| October 22, 2026 | 0.6826M |
| October 21, 2026 | 0.6156M |
| October 20, 2026 | 0.6596M |
| October 19, 2026 | 0.7539M |
| October 16, 2026 | 1.152M |
| October 15, 2026 | 1.464M |
| October 14, 2026 | 1.706M |
| October 13, 2026 | 1.913M |
| October 12, 2026 | 1.983M |
| October 09, 2026 | 1.446M |
| October 08, 2026 | 2.208M |
| October 07, 2026 | 2.026M |
| October 06, 2026 | 2.000M |
| Date | Value |
|---|---|
| October 05, 2026 | 1.948M |
| October 02, 2026 | 1.973M |
| October 01, 2026 | 2.000M |
| September 30, 2026 | 1.931M |
| September 29, 2026 | 1.948M |
| September 28, 2026 | 1.965M |
| September 25, 2026 | 1.931M |
| September 24, 2026 | 1.983M |
| September 23, 2026 | 1.948M |
| September 22, 2026 | 2.225M |
| September 21, 2026 | 2.381M |
| September 18, 2026 | 2.329M |
| September 17, 2026 | 1.879M |
| September 16, 2026 | 2.086M |
| September 15, 2026 | 2.260M |
| September 14, 2026 | 2.588M |
| September 11, 2026 | 3.038M |
| September 10, 2026 | 2.658M |
| September 09, 2026 | 2.741M |
| September 08, 2026 | 2.952M |
| September 04, 2026 | 3.004M |
| September 03, 2026 | 2.727M |
| September 02, 2026 | 3.298M |
| September 01, 2026 | 2.744M |
| August 31, 2026 | 3.021M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lexaria Bioscience Corp. | 3.578M |
| Mentari Therapeutics, Inc. | 86.76M |
| Target Group, Inc. (Canada) | 11.66M |
| NervGen Pharma Corp. | 87.27M |
| Milestone Pharmaceuticals, Inc. | 63.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.691M |
| Total Expenses (Quarterly) | 1.691M |
| EPS Diluted (Quarterly) | -1.045 |
| Earnings Yield | -324.8% |
| Normalized Earnings Yield | -337.43 |